Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.
Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbrielli A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Melisi D, et al. Among authors: zecchetto c. Eur J Cancer. 2024 Jan;196:113430. doi: 10.1016/j.ejca.2023.113430. Epub 2023 Nov 11. Eur J Cancer. 2024. PMID: 37995598 Free article. Clinical Trial.
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.
Bencivenga M, Torroni L, Dal Cero M, Quinzii A, Zecchetto C, Merz V, Casalino S, Taus F, Pietrobono S, Mangiameli D, Filippini F, Alloggio M, Castelli C, Iglesias M, Pera M, Melisi D. Bencivenga M, et al. Among authors: zecchetto c. J Pers Med. 2023 Aug 24;13(9):1294. doi: 10.3390/jpm13091294. J Pers Med. 2023. PMID: 37763062 Free PMC article.
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.
Pietrobono S, Sabbadini F, Bertolini M, Mangiameli D, De Vita V, Fazzini F, Lunardi G, Casalino S, Scarlato E, Merz V, Zecchetto C, Quinzii A, Di Conza G, Lahn M, Melisi D. Pietrobono S, et al. Among authors: zecchetto c. Cancer Res. 2024 Jan 2;84(1):118-132. doi: 10.1158/0008-5472.CAN-23-0104. Cancer Res. 2024. PMID: 37738399 Free PMC article. Clinical Trial.
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Procaccio L, Merz V, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, Pinto C, Zecchetto C, Barsotti G, De Vita F, Milella M, Antonuzzo L, Scartozzi M, Zaniboni A, Spadi R, Casalino S, Bergamo F, De Toni C, Melisi D, Lonardi S. Procaccio L, et al. Among authors: zecchetto c. Cancer Med. 2023 Jul;12(13):14337-14345. doi: 10.1002/cam4.6111. Epub 2023 Jun 6. Cancer Med. 2023. PMID: 37278395 Free PMC article.
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab.
Zecchetto C, Quinzii A, Casalino S, Gaule M, Pesoni C, Merz V, Pietrobono S, Mangiameli D, Pasquato M, Milleri S, Giacopuzzi S, Bencivenga M, Tomezzoli A, de Manzoni G, Melisi D. Zecchetto C, et al. J Pers Med. 2023 Mar 11;13(3):508. doi: 10.3390/jpm13030508. J Pers Med. 2023. PMID: 36983691 Free PMC article.
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D. Merz V, et al. Among authors: zecchetto c. Front Surg. 2022 May 4;9:866173. doi: 10.3389/fsurg.2022.866173. eCollection 2022. Front Surg. 2022. PMID: 35599791 Free PMC article. Review.
29 results